Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer

Yen Han Tseng, Jen Fu Shih, Heng Sheng Chao, Yuh Min Chen

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

Background. Later line chemotherapy (≥2nd lines) such as Docetaxel or immunother- apy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted. Methods. We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. Results. Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25%). The disease control rate was 60.7% (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type. Conclusions. TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.

原文英語
文章編號e7767
期刊PeerJ
2019
發行號9
DOIs
出版狀態已發佈 - 一月 1 2019

ASJC Scopus subject areas

  • 神經科學 (全部)
  • 生物化學、遺傳與分子生物學 (全部)
  • 農業與生物科學 (全部)

指紋

深入研究「Efficacy of paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer」主題。共同形成了獨特的指紋。

引用此